NASDAQ: TBPHTheravance Biopharma Inc Stock
$16.84+0.03 (+0.18%)
Updated Jul 21, 2026
TBPH Price
$16.84
Fair Value Price
N/A
Market Cap
$868.15M
52 Week Low
$10.82
52 Week High
$21.03
P/E
7.42x
P/B
2.99x
P/S
7.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$109.78M
Earnings
$114.54M
Gross Margin
100%
Operating Margin
126.38%
Profit Margin
104.3%
Debt to Equity
0.63
Operating Cash Flow
$269M
Beta
0.62
Next Earnings
Aug 11, 2026
Ex-Dividend
N/A
Next Dividend
N/A
TBPH Overview
Theravance Biopharma, Inc., a biopharmaceutical company, develops and commercializes medicines in the United States. It offers YUPELRI, an once-daily, nebulized long-acting muscarinic antagonist for the treatment of chronic obstructive pulmonary disease (COPD); and Ampreloxetine an investigational, once-daily norepinephrine reuptake inhibitor, Which is in Phase 3 clinical trials for symptomatic neurogenic orthostatic hypotension (nOH) in patients with Multiple System Atrophy (MSA). It has a strategic collaboration agreement with Viatris Inc. for the development and commercialization of revefenacin, including YUPELRI inhalation solution. Theravance Biopharma, Inc. was incorporated in 2013 and is based in South San Francisco, California.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine TBPH's potential to beat the market
- TBPH doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
TBPH
RankedUnranked of 464
RankedUnranked of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $254.22 | A | |
| $11.20 | A | |
| $8.78 | A |
Be the first to know about important TBPH news, forecast changes, insider trades & much more!
TBPH News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how TBPH scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
TBPH is forecast by analysts to be unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TBPH is good value based on its earnings relative to its share price (7.42x), compared to the US market average (12.07x)
P/E vs Market Valuation
TBPH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 30 more TBPH due diligence checks available for Premium users.
Valuation
TBPH price to earnings (PE)
For valuing profitable companies with steady earnings
Company
7.42x
Industry
21.35x
Market
12.07x
TBPH is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
TBPH is good value based... subscribe to Premium to read more.
P/E vs Market Valuation
TBPH price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
2.99x
Industry
5.42x
TBPH is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
TBPH's financial health
Profit margin
Revenue
$17.7M
Net Income
-$4.9M
Profit Margin
-27.9%
TBPH's Earnings (EBIT) of $138.73M... subscribe to Premium to read more.
Interest Coverage Financials
TBPH's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$472.3M
Liabilities
$181.7M
Debt to equity
0.63
TBPH's short-term assets ($417.63M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TBPH's short-term assets ($417.63M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TBPH's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TBPH's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$73.3M
Investing
$52.6M
Financing
-$5.6M
TBPH's operating cash flow ($268.78M)... subscribe to Premium to read more.
Debt Coverage Financials
TBPH vs Biotech Stocks
Theravance Biopharma Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.